<p>A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States</p>

    Michael Benigno, Kathryn Anastassopoulos, Arash Mostaghimi, Margarita Udall, Shoshana Daniel, Joseph C. Cappelleri, Pratibha Chander, Peter Wahl, Jennifer Lapthorn, Laura Kauffman, Linda Chen, Elena Peeva
    TLDR Alopecia areata affects many in the US, impacting quality of life, with limited treatment options.
    This study estimated the prevalence of alopecia areata (AA) in the US through an online survey of 45,016 participants, with a subset undergoing clinician evaluation. The self-reported point prevalence of AA was 1.14%, with a lifetime prevalence of 2.51%. Clinician-adjudicated prevalence was 0.21%, potentially rising to 0.48% with sensitivity analysis. The study highlighted discrepancies between self-reported and clinician-adjudicated data, particularly for mild AA, and emphasized the limited treatment options for severe cases. It underscored the significant impact of AA on quality of life and the need for targeted treatments. The study was funded by Pfizer Inc., with potential conflicts of interest disclosed due to financial ties to the company.
    Discuss this study in the Community →

    Research cited in this study

    8 / 8 results

    Related Research

    5 / 5 results